Table 1 Baseline demographic and clinical data: Efficacy Sample.
|  | Naïve patients | Pre-treated | Total |
|---|---|---|---|
Total | 1785 (38.5%) | 2854 (61.5%) | 4639 |
Gender (f/m) | 882/903 | 1605/1249 | 2487/2152 |
Mean age ± SD | 57.9 ± 12.7 | 63.6 ± 12.3 | 61.4 ± 12.8 |
Baseline SBP (Mean ± SD) | 168.8 ± 17.8 | 163.5 ± 19.1 | 165.5 ± 18.8 |
Baseline DBP (Mean ± SD) | 101.2 ± 8.6 | 96.3 ± 10.4 | 98.2 ± 10.0 |
Diabetes | 165 (9.2%) | 492 (17.2%) | 657 (14.2%) |
ISH | 79 (4.4%) | 408 (14.3%) | 487 (10.5%) |
WHO-risk | Â | Â | Â |
   Low (<15%) | 37 (2.1%) | 101 (3.5%) | 138 (3.0%) |
   Medium (15–20%) | 837 (46.9%) | 1190 (41.7%) | 2027 (43.7%) |
   High (20–30%) | 274 (15.4%) | 526 (18.4%) | 800 (17.2%) |
   Very high (>30%) | 637 (35.7%) | 1037 (36.3%) | 1674 (36.1%) |